2. Search Result
Search Result
Results for "

and CDK2

" in MedChemExpress (MCE) Product Catalog:

261

Inhibitors & Agonists

3

Peptides

10

Natural
Products

4

Isotope-Labeled Compounds

2

Click Chemistry

7

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162255
    CDK2-IN-23

    		CDK Cancer
    CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .
    CDK2-IN-23
  • HY-W478102
    CDK2-IN-13

    		CDK Cancer
    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 µM. CDK2-IN-13 can be used in research of cancer .
    CDK2-IN-13
  • HY-164664
    CDK2-IN-30

    		CDK Cancer
    CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 value ≤20 nM. CDK2-IN-30 can be used in tumor research .
    CDK2-IN-30
  • HY-143497
    HDAC1/2 and CDK2-IN-1

    		HDAC CDK Apoptosis Cancer
    HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .
    HDAC1/2 and CDK2-IN-1
  • HY-144810
    CDK2-IN-8

    		CDK Cancer
    CDK2-IN-8 is a potent CDK2 inhibitor with an IC50 of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .
    CDK2-IN-8
  • HY-160643
    CDK2-IN-27

    		CDK Cancer
    CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC50 values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .
    CDK2-IN-27
  • HY-144811
    CDK2-IN-9

    		CDK Apoptosis Cancer
    CDK2-IN-9 is a potent CDK2 inhibitor with an IC50 of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .
    CDK2-IN-9
  • HY-159805
    CDK2-IN-31

    		CDK Cancer
    CDK2-IN-31 (compound I-125A) is a CDK2 inhibitor. CDK2-IN-31 can be used in cancer research .
    CDK2-IN-31
  • HY-151580
    CDK2-IN-14

    		CDK Cancer
    CDK2-IN-14 (compound 4f) is a highly selective CDK2 inhibitor. CDK2-IN-14 can be used in research of cancer .
    CDK2-IN-14
  • HY-148651
    CDK2-IN-15

    		CDK Cardiovascular Disease Cancer
    CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC50 of 2.9 μM. CDK2-IN-15 can be used for cancer research .
    CDK2-IN-15
  • HY-170897
    CDK2-IN-40

    		CDK Cancer
    CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits CDK2/Cyclin E1 with an IC50 of ≤ 10 nM .
    CDK2-IN-40
  • HY-169683
    CDK2-IN-39

    		CDK Cancer
    CDK2-IN-39 (compound 4) is a CDK2 inhibitor .
    CDK2-IN-39
  • HY-163357
    CDK2/MDM2-IN-1

    		CDK MDM-2/p53 Cancer
    CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .
    CDK2/MDM2-IN-1
  • HY-139651
    CDK2-IN-7

    		CDK Cancer
    CDK2-IN-7 is a CDK2 inhibitor for researching cancer (IC50 < 50 nM).
    CDK2-IN-7
  • HY-160556
    CDK2-IN-26

    		CDK Cancer
    CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .
    CDK2-IN-26
  • HY-169910
    CDK2 degrader 4

    		CDK Cancer
    CDK2 degrader 4 (compound 104) is a potent CDK2 degrader. CDK2 degrader 4 has the potential for the research of cancer .
    CDK2 degrader 4
  • HY-170441
    CDK2-IN-36

    		CDK Cancer
    CDK2-IN-36 (compound1) is a CDK2 inhibitor with anticancer activity .
    CDK2-IN-36
  • HY-151580S
    CDK2-IN-14-d3

    		CDK Cancer
    CDK2-IN-14-d3 is a potent and selective CDK2 inhibitor. CDK2-IN-14-d3 can be used in research of cancer .
    CDK2-IN-14-d3
  • HY-173203
    CDK2-IN-43

    		CDK Cancer
    CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field .
    CDK2-IN-43
  • HY-155441
    CDK2-IN-20

    		CDK Cancer
    CDK2-IN-20 (compound 3b) is an inhibitor of CDK2. CDK2-IN-20 has cytotoxicity on tumor cells presenting an IC50 range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .
    CDK2-IN-20
  • HY-155966
    CDK2-IN-19

    		CDK Cancer
    CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .
    CDK2-IN-19
  • HY-172872
    CDK2-IN-45

    		CDK Apoptosis Cancer
    CDK2-IN-45 is a CDK2 inhibitor (IC50: 0.64 μM). CDK2-IN-45 inhibits the proliferation of DU-145 and PC-3 cell lines with IC50 of 2.20 μM and 4.17 μM, respectively. CDK2-IN-45 induces G0/G1 cell cycle arrest and apoptosis. CDK2-IN-45 can be used in prostate cancer research .
    CDK2-IN-45
  • HY-150573
    CDK2-IN-12

    		CDK Carbonic Anhydrase Cancer
    CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
    CDK2-IN-12
  • HY-176174S
    CDK2-IN-46

    		Isotope-Labeled Compounds CDK Cancer
    CDK2-IN-46 (compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .
    CDK2-IN-46
  • HY-112460
    CDK2-IN-3

    		CDK Cancer
    CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an IC50 of 60 nM .
    CDK2-IN-3
  • HY-169246
    CDK2-IN-32

    		CDK Apoptosis Cancer
    CDK2-IN-32 (Compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC50 of 28.52 μM .
    CDK2-IN-32
  • HY-169912
    CDK2 degrader 5

    		CDK Cancer
    CDK2 degrader 5 (compound 12) is a degrader for CDK2, with the Dmax of >50% and ≤80% in HiBiT Assay. CDK2 degrader 5 plays an important role in cancer research .
    CDK2 degrader 5
  • HY-161291
    CDK2-IN-25

    		CDK Cancer
    CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC50 of 0.149 μM .
    CDK2-IN-25
  • HY-168057
    PROTAC CDK2 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC50 of 100-500 nM .
    PROTAC CDK2 Degrader-1
  • HY-170442
    CDK2-IN-37

    		CDK Cancer
    CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase (CDK2) inhibitor with anti-cancer activity .
    CDK2-IN-37
  • HY-161463
    CDK2-IN-28

    		CDK Cancer
    CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .
    CDK2-IN-28
  • HY-176444
    CDK2 degrader 6

    		CDK Cancer
    CDK2 degrader 6 (compound 6) is an orally active and potent CDK2 degrader with a DC50 of 46.5 nM. CDK2 degrader 6 can be used in the study of breast cancer .
    CDK2 degrader 6
  • HY-173224
    CDK2/PIM1-IN-1

    		CDK Pim Cancer
    CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .
    CDK2/PIM1-IN-1
  • HY-155602
    CDK2-IN-18

    		CDK Cancer
    CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC50s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .
    CDK2-IN-18
  • HY-151573
    EGFR/CDK2-IN-1

    		EGFR CDK Cancer
    EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .
    EGFR/CDK2-IN-1
  • HY-173310
    CDK2-IN-44

    		CDK Cancer
    CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .
    CDK2-IN-44
  • HY-164827
    CDK2 degrader 3

    		CDK Cancer
    CDK2 degrader 3 can selectively degrade CDK2 and has anti-tumor activity .
    CDK2 degrader 3
  • HY-163814
    CDK2 degrader 1

    		PROTACs CDK Cancer
    CDK2 degrader 1 (Compound 3) is an orally active cyclin-dependent kinase 2 (CDK2) degrader based on PROTAC technology. CDK2 degrader 1 binds to cereblon to induce ubiquitination and subsequent proteasomal degradation of the CDK2. CDK2 degrader 1 is used in the research of a wide range of cancers (Red: spiro[3.3]heptan-2- ylmethyl carbonochloridate; Blue: N,N-diisopropylethylamine; Black: linker) .
    CDK2 degrader 1
  • HY-172153
    CDK2-IN-41

    		CDK Reactive Oxygen Species Apoptosis Cancer
    CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .
    CDK2-IN-41
  • HY-117535
    CDK2-IN-4
    2 Publications Verification

    		 CDK Cancer
    CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM) .
    CDK2-IN-4
  • HY-159155
    CDK2/4-IN-1

    		CDK Microtubule/Tubulin Cancer
    CDK2/4-IN-1 (compound B-4a) is a CDK2/4 inhibitor and a tubulin polymerization inhibitor. CDK2/4-IN-1 can be used in cancer research .
    CDK2/4-IN-1
  • HY-150572
    CDK2-IN-11

    		CDK Carbonic Anhydrase Cancer
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .
    CDK2-IN-11
  • HY-169048
    CDK2/4-IN-2

    		CDK Cancer
    CDK2/4-IN-2 (compound 56) is a CDK2 and CDK4 dual inhibitor with IC50s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .
    CDK2/4-IN-2
  • HY-P3730
    Cdk2/Cyclin Inhibitory Peptide I

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
    Cdk2/Cyclin Inhibitory Peptide I
  • HY-P3731
    Cdk2/Cyclin Inhibitory Peptide II

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
    Cdk2/Cyclin Inhibitory Peptide II
  • HY-149436
    CDK2/Bcl2-IN-1

    		CDK Cancer
    CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC50=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .
    CDK2/Bcl2-IN-1
  • HY-148213
    CDK2/4/6-IN-1

    		CDK Cancer
    CDK2/4/6-IN-1(example 29) is a CDK2/4/6 inhibitor with IC50 values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CDK2/4/6-IN-1
  • HY-168845
    CDK2/9-IN-1

    		CDK Apoptosis Cancer
    CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC50 values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity .
    CDK2/9-IN-1
  • HY-123045
    PNU-292137

    		CDK Cancer
    PNU-292137 is an orally active, potent CDK2 inhibitor with IC50s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .
    PNU-292137
  • HY-156115
    EGFR/CDK2-IN-3

    		EGFR CDK Cancer
    EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM .
    EGFR/CDK2-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: